Indian pharma cos look to acquire niche portfolios: Report
The Dollar Business Bureau India’s major pharmaceuticals companies are now looking to acquire niche product portfolios in several regulated markets across the world, indicated a report on Tuesday. "Recently, selected innovators have taken a call to exit their generics business and concentrate on branded/patented businesses creating billion dollar acquisition opportunities for large Indian pharma players in the regulated markets," said the report published by ICICI Securities. The country’s largest ten pharmaceutical companies, which are incidentally cash-rich, are hungry to acquire companies with their niche product portfolios. The report pointed out that the top Indian pharma companies have plethora of funds, and they can raise capital easily from debt and equity capital markets. In September, UCB sold Kremers Urban to Lannett for $1.23 billion and India-based generics portfolios ...
Regulatory standards pose major challenge for Indian pharma industry
Sai Nikesh | The Dollar Business The Indian pharmaceutical sector has to face many challenges due to issues related to regulatory compliance and international trade negotiations, say industry leaders. In the new Foreign Trade Policy, the government has taken several steps to improve the pharma sector. A fund of Rs.50,000 crore has also been allocated for improving regulatory standards. “However, issues relating to regulatory standards are posing challenges,” said K Satish Reddy, Chairman, Dr Reddy’s Laboratories Limited. Speaking at the Pharma CEOs Conclave 2015 in Hyderabad on Wednesday, Reddy said that there is a need for a better coordination between the government and the industry to resolve these kinds of issues. “Few challenges also exist in case of India’s global-level trade ...
